Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Questions Soliris Survival Benefit; Adds Listings From MSD, Novartis, Janssen To PBS

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)

You may also be interested in...



More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study

PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development

More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study

PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development

More Oncology Drugs Available In U.S., But Australians Pay 30% Less - Tufts Study

The evidence-based approach adopted by Australia has led to lower prices, improving the affordability of those medications considered cost-effective for payers and patients by the reimbursement authority, the report says.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel